| Trial ID: | L5450 |
| Source ID: | NCT05887999
|
| Associated Drug: |
Ly3532226
|
| Title: |
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: LY3532226|DRUG: Placebo
|
| Outcome Measures: |
Primary: Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia, PD: AUC60-120min of plasma glucagon during the insulin-induced hypoglycemia, Predose up to 120 mins postdose | Secondary: The amount of exogenous glucose infused to maintain a plasma glucose level of >2.5 millimole per liter (mmol/L), after the insulin infusion is terminated., The amount of exogenous glucose infused to maintain a plasma glucose level of \>2.5 mmol/L, after the insulin infusion is terminated., Predose up to 120 mins postdose|Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT), Change from Baseline in Fasting and Post meal Glucose during sMMTT, Predose up to 120 mins postdose|Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT, Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT, Predose up to 120 mins postdose
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2023-06-12
|
| Completion Date: |
2024-02-21
|
| Results First Posted: |
|
| Last Update Posted: |
2024-03-26
|
| Locations: |
ProSciento, Inc, Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05887999
|
